Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2007-09-17
- Lead Sponsor
- VA Greater Los Angeles Healthcare System
- Target Recruit Count
- 23
- Registration Number
- NCT00304421
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
Sleep Disorders and Gastroesophageal Reflux Disease (GERD)
- Conditions
- InsomniaGERD
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2007-04-27
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT00287391
- Locations
- 🇺🇸
UNC Gastroenterology and UNC Sleep Disorders Center, Chapel Hill, North Carolina, United States
Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Drug: Standard dose (once daily) PPI plus low-dose antidepressantDrug: Double dose PPI plus evening placebo
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 150
- Registration Number
- NCT00251732
- Locations
- 🇺🇸
Southern Arizona VA Health Care System, Tucson, Arizona, United States
E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2010-04-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 629
- Registration Number
- NCT00236184
- Locations
- 🇺🇸
Jeffrey L. Newman, Vista, California, United States
A Study of Rabeprazole and Pantoprazole on Stomach Acid and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease (GERD) and a History of Nighttime Heartburn
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2010-04-28
- Lead Sponsor
- PriCara, Unit of Ortho-McNeil, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00237367
A Study of Efficacy and Safety of "On-demand" Maintenance Therapy With Rabeprazole in Patients With Non-erosive Reflux Disease (NERD)
- Conditions
- Gastroesophageal RefluxHeartburn
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2010-11-30
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 422
- Registration Number
- NCT00236392
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2009-11-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 619
- Registration Number
- NCT00236197
- Locations
- 🇺🇸
New York Center For Clinical Research, Lake Success, New York, United States
Improvement in Bronchial Asthma in Patients With Extraesophageal Reflux After Acid Suppression
- Conditions
- Bronchial AsthmaGastroesophageal Reflux
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Ponce Gastroenterology Research
- Target Recruit Count
- 40
- Registration Number
- NCT00234117
- Locations
- 🇵🇷
Ponce Gastroentrology Research, Ponce, Puerto Rico
A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)
- Conditions
- Gastroesophageal RefluxHeartburn
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
- Target Recruit Count
- 191
- Registration Number
- NCT00216489
Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.
- Conditions
- Helicobacter InfectionsBacterial Infections
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-04-26
- Lead Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
- Target Recruit Count
- 80
- Registration Number
- NCT00216450
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.